Cargando…

Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy

Thalidomide analogues (or immunomodulatory imide drugs, IMiDs) are cornerstones in the treatment of multiple myeloma (MM). These drugs bind Cereblon (CRBN), a receptor for the Cullin-ring 4 ubiquitin-ligase (CRL4) complex, to modify its substrate specificity. IMiDs mediate CRBN-dependent engagement...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costacurta, Matteo, He, Jackson, Thompson, Philip E., Shortt, Jake
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623651/ https://www.ncbi.nlm.nih.gov/pubmed/34834536 http://dx.doi.org/10.3390/jpm11111185

Ejemplares similares

Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma
por: Chang, Xiubao, et al.
Publicado: (2017)

Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma
por: Costacurta, Matteo, et al.
Publicado: (2020)

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
por: Butrym, Aleksandra, et al.
Publicado: (2017)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples
por: Ren, Yan, et al.
Publicado: (2016)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

Expression, mutation, and methylation of cereblon‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma
por: Tachita, Takuto, et al.
Publicado: (2020)

Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma
por: Charliński, Grzegorz, et al.
Publicado: (2021)

Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine
por: Sato, Tomomi, et al.
Publicado: (2021)

Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival
por: Xu, Qinqin, et al.
Publicado: (2016)

Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS
por: Wester, R., et al.
Publicado: (2023)

Chemical Ligand Space of Cereblon
por: Boichenko, Iuliia, et al.
Publicado: (2018)

Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators
por: Nishiguchi, Gisele, et al.
Publicado: (2021)

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2014)

Structural Dynamics of the Cereblon Ligand Binding Domain
por: Hartmann, Marcus D., et al.
Publicado: (2015)

Structural basis of thalidomide enantiomer binding to cereblon
por: Mori, Tomoyuki, et al.
Publicado: (2018)

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
por: Gasic, Ivana, et al.
Publicado: (2020)

UDP-glucose, cereblon-dependent proinsulin degrader
por: Cho, Jaeyong, et al.
Publicado: (2022)

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways
por: Karagoz, Kubra, et al.
Publicado: (2022)

Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma
por: Abramson, Hanley N.
Publicado: (2023)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Mitochondrial cereblon functions as a Lon-type protease
por: Kataoka, Kosuke, et al.
Publicado: (2016)

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
por: Zhu, Yuan Xiao, et al.
Publicado: (2019)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

UBE2G1 governs the destruction of cereblon neomorphic substrates
por: Lu, Gang, et al.
Publicado: (2018)

Accessing three-branched high-affinity cereblon ligands for molecular glue and protein degrader design
por: Kuchta, Robert, et al.
Publicado: (2023)

Molecular mechanisms in multiple myeloma drug resistance
por: Nikesitch, Nicholas, et al.
Publicado: (2016)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

In silico analysis of enantioselective binding of immunomodulatory imide drugs to cereblon
por: Murai, Takahiro, et al.
Publicado: (2016)

Susceptibility of pentylenetetrazole-induced seizures in mice with Cereblon gene knockout
por: Jeon, Seung-Je, et al.
Publicado: (2020)

UDP-Glucose: A Cereblon-Dependent Glucokinase Protein Degrader
por: Cho, Jaeyong, et al.
Publicado: (2022)

Targeted protein degradation bypassing cereblon and von Hippel-Lindau
por: Lu, Wenchao
Publicado: (2023)

PB1958: IN SILICO ANALYSIS OF SYNONYMOUS AND NON-SYNONYMOUS SNPS OF THE HUMAN CEREBLON (CRBN) GENE: AN IMPORTANT GENE IN IMMUNOMODULATORY DRUGS (IMIDS)-BASED TREATMENT OF MULTIPLE MYELOMA PATIENTS
por: Güler, M., et al.
Publicado: (2022)

Adhesion molecules in multiple myeloma oncogenesis and targeted therapy
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Targeting p53 by small molecule p53 activators in multiple myeloma
por: Saha, Manujendra N, et al.
Publicado: (2012)

Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation
por: Shi, Qinglin, et al.
Publicado: (2017)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

CRL4-Cereblon complex in Thalidomide Embryopathy: a translational investigation
por: Kowalski, Thayne Woycinck, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1g4a0272ppneknfj7rcft82cfh